How it works
Methodology
From a goal, to a status, to a source, to a price. Each step and the rule behind it.
1.Goals come first
The site is organized by what a reader wants to change. There are 5 goals: weight, sexual health, longevity, recovery and sleep.
A peptide appears under a goal because readers look it up for that goal. That placement is a filing decision. It is not a claim that the peptide works for it.
2.The regulatory gate
Every peptide has one status. The status decides what the site may show.
- FDA-approved or Legal to compound: research, seller links and prices.
- Approved as a brand only: the branded product only. A compounded version gets no seller link and no price.
- Research only: research only. No seller, no price.
- Status not yet reviewed: treated as research-only until its source is read.
Where FDA limits a status to certain forms, the gate applies per form. A topical form can pass while an injection of the same peptide does not.
Each status is read from an FDA document and dated. It is re-read when FDA publishes a change. One function applies the gate, and the goal pages, prices and seller lists all call it.
3.The register, as read
| Peptide | Status | Rests on | Read |
|---|---|---|---|
| Semaglutide | FDA-approved | Wegovy (semaglutide) injection, NDA 215256, approved for chronic weight management. Source | September 2026 |
| Tirzepatide | FDA-approved | Zepbound (tirzepatide) injection, NDA 217806, approved for chronic weight management. Source | September 2026 |
| Liraglutide | FDA-approved | Saxenda (liraglutide) injection, NDA 206321, approved December 23, 2014 for chronic weight management. Source | September 2026 |
| Orforglipron | FDA-approved | Foundayo (orforglipron) tablets, NDA 220934, approved April 1, 2026 for chronic weight management. Source | September 2026 |
| Sermorelin | Legal to compound | Component of an FDA-approved drug (GEREF, sermorelin acetate). FDA determined in 2013 that GEREF was not withdrawn from sale for reasons of safety or effectiveness. Source | September 2026 |
| NAD+ | Legal to compound | Nicotinamide Adenine Dinucleotide (NAD) is in 503A Category 1 (bulk drug substances under evaluation), covered by FDA's interim compounding policy (list updated May 14, 2026). Source | September 2026 |
| Glutathione | Legal to compound | Glutathione is in 503A Category 1 (bulk drug substances under evaluation), covered by FDA's interim compounding policy (list updated May 14, 2026). Source | September 2026 |
| GHK-Cu | Legal to compound | "GHK-Cu (except for injectable routes of administration)" is in 503A Category 1 (list updated May 14, 2026). The injectable route is on no list. Source | September 2026 |
| PT-141 (bremelanotide) | FDA-approved | Vyleesi (bremelanotide) injection, NDA 210557, approved June 21, 2019 for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Source | September 2026 |
| Tesamorelin | Approved as a brand only | Approved only as Egrifta, for excess abdominal fat in adults with HIV-associated lipodystrophy. Its label says it is not indicated for weight loss. Egrifta became a biologic (BLA) on March 23, 2020, and FDA says compounded versions of these products do not qualify for the 503A or 503B compounding exemptions. Source | September 2026 |
| MOTS-c | Research only | On no 503A list (not in Categories 1–3 of the May 14, 2026 update). The FDA's compounding advisory committee voted 7–5 (two abstentions) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking. Source | September 2026 |
| BPC-157 | Research only | On no 503A list (removed from Category 2 in April 2026, never in Category 1). The FDA's compounding advisory committee voted 8–6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking. Source | September 2026 |
| Kisspeptin | Research only | Kisspeptin-10 is in 503A Category 2 (bulk drug substances that raise significant safety risks), placed there September 29, 2023 and still listed in the May 14, 2026 update. FDA cites a possible risk of immunogenicity and peptide-related impurities, and says it has no, or only limited, safety information for the proposed routes. Source | September 2026 |
4.How evidence is sourced
Findings come from the study itself. A paper is identified by its PubMed ID where it has one, and linked to its record.
Every finding names what was studied: people, animals or cells. For people, the page gives the number studied, the dose and the duration where the paper reports them.
Animal and cell results are reported as animal and cell results. Where no human study exists, the page says so.
5.How prices are read
A price is the figure the seller publishes on its own site. It carries the date it was read. No price here was confirmed by completing a checkout.
Some sellers publish a membership or program fee you cannot avoid, separate from the drug price. That fee is added before any comparison. The total is our arithmetic on the seller’s own figures.
A monthly price under $50 for a peptide whose dose steps up is treated as an introductory offer. It is marked promotional and is not used to rank.
6.Order on a seller list
On a ranked board, partners are listed first and labeled Partner. That part of the order is commercial, and it is disclosed on the board itself. Every other seller list on this site (a guide’s sellers, a goal’s sellers) is ordered by fit or alphabetically, never by partnership, and says which.
After the partner group, sellers are ordered by an interim scoring function. It reads these published facts about each seller today:
- Price transparency
- Honest headline
- Dose-ladder pricing
- State coverage
- Molecule and form breadth
Whether a seller pays us is not an input to its score. A test flips a seller’s status and checks that its score does not move.
0 of the 5 sellers ranked here pay us a commission. The seller the scoring function places first, CoreAge Rx, is not one of them. See disclosures for what a partner can and cannot get.
7.What this method does not do
- It does not rate whether a peptide works.
- It does not judge a seller’s prescribers.
- It does not give medical advice. See the medical disclaimer.